(ATPC) Agape ATP Common Stock - Ratings and Ratios

Agape ATP Corporation (NASDAQ:ATPC) operates as an investment holding company focused on health and wellness products and advisory services in Malaysia. The company offers a diversified portfolio of programs and products under four main brands: ATP Zeta Health Program, ENERGETIQUE, BEAUNIQUE, and E.A.T.S. These programs encompass a range of health and wellness solutions, including nutritional supplements, skincare products, and health therapies. The companys product lineup includes ATP1s Survivor Select, a nutrient-rich supplement for metabolism support; ATP3 Ionized Cal-Mag, a calcium and magnesium supplement; ATP4 Omega Blend, an essential fatty acid blend; ATP5 BetaMaxx, an immune enhancer; and AGN-Vege Fruit Fiber, a formulation for digestive health. Additionally, the company markets BEAUNIQUE products such as Mito+, an antioxidant drink, and Trim+, a carbohydrate digestive enzyme inhibitor. Under the ENERGETIQUE brand, it offers energy masks and hyaluronic acid serum, while the Livo5 brand includes soy protein isolate powder and antioxidants. Agape ATP Corporation also promotes wellness lifestyles through online content, events, and campaigns, and provides health therapies. The company has a strategic collaboration to launch LEGA, a respiratory care device.

Founded in 2016 and headquartered in Kuala Lumpur, Malaysia, Agape ATP Corporation is listed on the NASDAQ under the ticker symbol ATPC. The company operates in the health care services sector, with a market capitalization of $4.03 million USD as of the latest data. Its stock has been trading with an average 20-day volume of 71,020 shares, with a last price of $1.08. The stocks technical indicators show an SMA20 of $1.04, SMA50 of $1.22, and SMA200 of $2.22, with an ATR of 0.23. Fundamental analysis reveals a P/B ratio of 1.48 and a P/S ratio of 2.98, though the company currently reports a negative return on equity (RoE) of -95.95. The forward P/E ratio is not available, indicating potential challenges in valuing the stock based on future earnings.